Cilomilast
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2004 (NCT00103922)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1- Mol. weight
- 343.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL511115 ↗
Also known as
- 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid
- ariflo
- ariflo
- ariflo
- cilomilast
- cilomilast
- cilomilast
- cilomilast
- cilomilast
- cis-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid
- cis-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid
- sb 207499
- sb-207499
- sb-207499
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00103922 | Phase 3 | Nov 1, 2004 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2004 |
1 organizations
Page 1 / 1